Jean-Baptiste Perot1,2, Clement M. Garin1,2, Salma Bougacha1,2,3,4, Alexandra Durr5,6, Marc Dhenain1,2, Sandrine Humbert7, Emmanuel Brouillet1,2, and Julien Flament1,2
1Molecular Imaging Research Center (MIRCen), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses, France, 2UMR 9199, Neurodegenerative Diseases Laboratory, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay, Fontenay-aux-Roses, France, 3Inserm UMR-S U1237, Normandie University, UNICAEN, GIP Cyceron, Caen, France, 4Inserm U1077 Neuropsychologie et Imagerie de la mémoire Humaine, Normandie University, UNICAEN, EPHE, CHU de Caen, Caen, France, 5Inserm UMR-S U1127, Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, Paris, France, 6Département de génétique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France, 7Inserm U1216, Grenoble Institut des Neurosciences (GIN), Univ. Grenoble Alpes, Grenoble, France
Synopsis
Huntington’s disease (HD) is an inherited
neurodegenerative disease characterized by cognitive, motor and psychiatric
symptoms. Despite tremendous efforts made during past years, there is a need for more predictive and functional biomarkers of disease
pathogenesis and progression. In the present study, we developed
a longitudinal and multimodal imaging protocol to elucidate HD pathogenesis in
a mouse model of HD and to evaluate the potential of different biomarkers. Our approach combining volume, gluCEST and magnetization transfer imaging and automated brain
segmentation revealed a brain network particularly vulnerable
in this model.
Introduction
Huntington’s
disease (HD) is an inherited neurodegenerative disease characterized by
cognitive, motor and psychiatric symptoms1. Atrophy of the striatum
as measured by MRI is one of the best biomarkers of disease progression in HD
gene carriers2. However, it provides very few information about HD
pathogenesis as it probably reflects long-term consequences of subtle
biological modifications that onset several years before atrophy occurrence. Thus,
there is a need to find more predictive, functional and earlier biomarkers to
better understand disease pathogenesis and to monitor its progression.
In
a previous work, we demonstrated the interest of gluCEST imaging3 in
the context of HD. In particular, we highlighted that corpus callosum (CC) was strongly
affected in a slowly progressive mouse model of HD4, confirming the
pivotal role of this structure in HD5 and, more generally, in
neurodegenerative diseases6-7. In the present study, we developed a
longitudinal and multimodal imaging protocol to elucidate HD pathogenesis in a
mouse model of HD and to evaluate the potential of different biomarkers.Methods
Mouse model:
Knock-in mice expressing mouse/human exon 1 containing 140 CAG repeats inserted
in the huntingtin (htt) gene were used8. Heterozygous mice for the htt gene
(Ki140, n=11) were compared to their relative age-matched littermates (WT,
n=12).
MRI protocol:
Animals were scanned longitudinally (10, 20, 34 and 48 weeks of age) on a
horizontal 11.7T Bruker magnet using a Cryoprobe. The MRI protocol was composed
by an anatomical image (TSE sequence, 48 slices, 0.25 x 0.25 mm², 0.5 mm slice
thickness), a gluCEST image (Magnetization Transfer Ratio (MTRasym) at ±3 ppm
calculated from a Zspectrum acquired between -5 and 5 ppm, B1=5 µT,
Tsat=1 s, WASSR correction for B0 inhomogeneity9)
and a magnetization transfer (MT) image (MTRasym at ±16 ppm, B1=10 µT,
Tsat=800 ms).
Automated Segmentation: Images were co-registered and automatically segmented using an atlas composed
of a high-resolution template and labels (34 regions, Fig.1), based on Allen
mouse brain atlas10. The registration pipeline used an in-house
python library (Sammba-MRI11, Fig. 1).
Statistical analysis: After
Shapiro-Wilk normality test, one-way ANOVA with repeated measures was used for
statistical analysis and was followed by Fisher LSD post-hoc test.Results
Morphometry: Based
on volume measurements, variation maps between WT and Ki140 mice were calculated
(Fig.2). Except for lateral ventricles, which were dilated in Ki140 mice
as early as 10 weeks, no structure showed any volume variation before 48 weeks. At
48 weeks, Ki140 mice exhibited a global atrophy of the brain (Fig.2, 4th
column). Volume variation as compared to WT was significant in the striatum (-4.2%,
p<0.05), in the dentate gyrus (-3.7%, p<0.05) and in several cortical regions
such as the motor (-3.5%, p<0.05), the piriform (-7.0%, p<0.001) and the retrosplenial cortexes (-5.2%, p<0.05).
GluCEST and MT imaging: GluCEST
and MT images were acquired on a single slice positioned based on our previous
work4 (Fig.3.a). A significant decrease of gluCEST signal was
measured in the CC of Ki140 mice at 48 weeks (Fig.3.b, -16%, p<0.05). HD mice also
exhibited a significant decrease of MT contrast in the striatum (Fig.3.c, -16%,
p<0.01) and in the septum (Fig.3.d, -25%, p<0.05) at 48 weeks.Discussion and conclusion
Based
on our longitudinal study, we observed only small modifications of MRI
parameters until 34 weeks, confirming that Ki140 mouse model is a very progressive
and mild model of HD8. Nonetheless, dilatation of lateral ventricles
suggested global atrophy of the brain, even at 10 weeks. Interestingly, the 16%
decrease of gluCEST contrast measured in the CC at 48 weeks was consistent with
our previous results4, confirming the specific alteration of this
structure. Concomitantly, we measured significant variations of macromolecular
content of tissues using MT imaging in the striatum of HD mice, a region known
to be particularly vulnerable in HD12, and in the septum. These
results suggest that myelin content could be affected in these regions. It could
also reflect neuronal atrophy and/or neurodegeneration at later stage of the
disease as suggested by atrophy of several brain structures (Fig.2). In order
to investigate a potential propagation of the defects, a future time point will
be acquired at 18 months of age.
Using
data from Allen Connectivity Atlas reference paper13, we figured out
that most of affected regions were strongly connected, forming a network
vulnerable to HD pathology in our mouse model of HD (Fig. 4). Most
interestingly, regions atrophied in Ki140 mice appeared to be mostly cortical,
while MT defects were located in striatal regions. Moreover, the cortico-striatal
connections, firmly appearing in this network, are reported to communicate via CC14, where we measured decrease of glutamate levels.
We
hypothesize that in the Ki140 HD model pathogenesis starts from
the striatum, the only region affected in both volumetric MRI and MT, or from the
lateral preoptic area, a small region of hypothalamus that seems central in
terms of connections with this network. Interestingly, metabolism changes have
been reported in the hypothalamus in HD patients15.
This
study emphasizes the relevance of our multimodal approach to better understand
pathogenesis of the disease and to highlight specific regions early affected in HD mouse models. Acknowledgements
Project was supported by eRARE ERA-Net (“TreatPolyQ”
ANR-17-RAR3-0008-01) and NeurATRIS, (“Investissements d'Avenir”, ANR-11-INBS-0011).
The 11.7T scanner was funded by NeurATRIS
(“Investissements d'Avenir”, ANR-11-INBS-0011).References
1. Walker, F.O., Huntington's disease. Lancet, 2007. 369(9557): p. 218-28.
2. Tabrizi, S.J. et al., Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol., 2013. 12(7): p.637-49.
3. Cai, K. et al. Magnetic resonance imaging of glutamate. Nat. Med., 2012. 18(2): p302-6.
4. Pépin, J. et al. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease. Neuroimage, 2016. 139: p53-64.
5. Phillips, O. et al. Tractography of the Corpus Callosum in Huntington’s Disease. PLoS ONE 8(9): e73280.
6. Goldman, J.G. et al. Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. Neurology, 2017. 88(13): 1265–1272.
7. Walterfang, M. et al. Shape analysis of the corpus callosum in Alzheimer’s disease and frontotemporal lobar degeneration subtypes. J. Alzheimer Dis., 2014. 40(4): 897–906.
8. Menalled, L.B. et al., Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats. The Journal of Comparative Neurology, 2003. 465: 11–26.
9. Kim, M. et al. Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn. Reson. Med., 2009. 61(6):1441-50.
10. Lein, E.S. et al. Genome-wide atlas of gene expression in the adult mouse brain, Nature, 2007. 445: 168-176.
11. Nadkarni, N.A. et al. Digital templates and brain atlas dataset for the mouse lemur primate.Data in Brief, 2018. P1178-1185.
12. André, V.M. et al. Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci.Ther., 2010. 16(3):163-78.
13. Oh, S.W. et al. A mesoscale connectome of the mouse brain. Nature, 2014. 508: 207-214.
14. Shepherd, G.M.G. Corticostriatal connectivity and its role in disease. Nat. Rev. Neurosci., 2013. 4(4): 278–291.
15. Petersén, A. et al. Hypothalamic and Limbic System Changes in Huntington’s Disease. Journal of Huntington’s Disease, 2012. 5–16.